SMEInst-05-2016-2017
SMEInst-05-2016-2017
107 projects · €112,881,738 total EU contribution (project-level) · 108 participating organizations · 21 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€112,881,738
Countries active
Participant organizations by country (headquarters in CORDIS).
- UK (15)
- Spain (13)
- France (11)
- Italy (10)
- SE (10)
- IL (8)
- Germany (7)
- Netherlands (6)
- PT (6)
- DK (4)
- IE (3)
- PL (3)
- AT (2)
- IS (2)
- NO (2)
- BE (1)
- CZ (1)
- EE (1)
- HU (1)
- SI (1)
- TR (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- AENITIS TECHNOLOGIES2 projects · FR
- EBERS2 projects · ES
- THE ZEBRAFISH LAB2 projects · ES
- METAFORA BIOSYSTEMS2 projects · FR
- SYMCEL2 projects · SE
- 2CUREX A/S1 projects · DK
- 2CUREX GMBH1 projects · DE
- AMADIX1 projects · ES
- AEQUOR1 projects · UK
- AGLARIS1 projects · UK
- ALLTOX1 projects · IT
- ALTRATECH LIMITED1 projects · IE
Projects
Page 3 of 11
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
First in class epithelial Barrier-enhancing medicine for respiratory diseases Bronchomycn · 761828 | H2020 | €50,000 | €71,429 | Details |
Integral cell-biology platform for the development of the first effective treatment of radiodermatitis. SkinXCare · 743887 | H2020 | €50,000 | €71,429 | Details |
Commercial feasibility study of a technology that multiplies blood stem cells to increase the success of transplants for cancer treatment BloodStemPLUS · 728580 | H2020 | €50,000 | €71,429 | Details |
Cell therapy for patients with chronic heart failure with proprietary cardiac-derived cells (CardAP cells) – “From the Heart to the Heart” CardAPcells · 735261 | H2020 | €50,000 | €71,429 | Details |
Next generation drug conjugates for cancer treatment Syndivia · 735764 | H2020 | €50,000 | €71,429 | Details |
The HepaRG-Bio-Artificial Liver: Feasibility of commercialization and expansion of business plan BALXPAND · 763310 | H2020 | €50,000 | €71,429 | Details |
A therapeutic vaccine candidate for lung cancer based on an exclusive cell line of Plasmacytoid Dendritic Cells (PDC*line) PDClungSME1 · 735097 | H2020 | €50,000 | €71,429 | Details |
MALLEABLE SURGICAL RETRACTOR FOR COMPLETE EXPOSURE OF MITRAL VALVE SALAS · 744712 | H2020 | €50,000 | €71,429 | Details |
BioResorbable Ostheosynthesis Implant BriScrew · 763129 | H2020 | €50,000 | €71,429 | Details |
A novel vaccine technology leading to accelerated availability of vaccines and improved delivery VACCELERAID · 744184 | H2020 | €50,000 | €71,429 | Details |